Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

Selling Assets Layout Semiconductors Shenzhen Strongteam Decoration Engineering "Renovating a New House" | Quick Announcement

① Shenzhen Strongteam Decoration Engineering announced today that it plans to sell some Assets, with a total amount not exceeding 0.4 billion yuan. This move is viewed by the market as the company aiming to streamline its operations for the 'second curve' growth. ② The company has been active in the relevant fields over the past six months, and its intention to transition into Semiconductors is already evident, but from publicly available information, it seems that its related projects in the Semiconductors sector are still in the preliminary stages.

cls.cnJan 13 10:56 ET

It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17, 2024 09:51 ET

"Waterproof King" Beijing Oriental Yuhong Waterproof Technology has once again crossed boundaries and taken over a landmark hotel in Chengdu from Sun Hongbin.

The 'waterproof leader' Beijing Oriental Yuhong waterproof technology took over the InterContinental Hotel in Chengdu Paradise Island Center, which was previously unsold for 1 billion yuan.

cls.cnNov 12, 2024 07:33 ET

Zhejiang Construction Investment Group plans to fully hold shares of multiple subsidiary companies. Chengdu State-owned Assets will exit as a shareholder after four years.

1. The performance has greatly declined, and Zhejiang Construction Investment Group is seeking equity acquisition; 2. The company plans to achieve full ownership of three subsidiaries; 3. The trade funds come from issuing shares to the controlling shareholder; 4. Chengdu State-owned Assets, the trading partner, invested 1 billion four years ago; 5. The target company's performance has significantly declined this year.

cls.cnNov 6, 2024 09:47 ET